Atlas Trials

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Clinical trial NCT04049266 · TERMINATED

Trial details

NCT number
NCT04049266
Sponsor
Kodiak Sciences Inc
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Wet Macular Degeneration
Start date
2019-10-08
Primary completion
2021-11-17
Enrollment
559

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.